Physician profile
Kenneth E Jones
NPI 1417018920
$8,726.98
in general payments reported to CMS, 2019-2025
51 companies · $904 in 2025
The $904 reported for 2025 was more than what 82% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $1,478 · 2021: $1,264 · 2022: $1,177 · 2023: $1,405 · 2024: $1,042 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,265 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,265.14 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,018.18 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,018.01 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $879.30 | 2019-2023 | |
| Novo Nordisk INC | $734.54 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $582.47 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.34 | 2019-2025 | Jardiance |
| Pfizer INC. | $361.33 | 2019-2025 | |
| Lundbeck LLC | $347.17 | 2023-2025 | Rexulti |
| Abbott Laboratories | $255.88 | 2019-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $230.14 | 2022-2025 | Rexulti |
| Amgen INC. | $228.13 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $174.18 | 2019-2023 | Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $167.56 | 2019-2023 | Seglentis, Livalo |
| Merck Sharp & Dohme LLC | $157.16 | 2019-2025 | Gardasil 9, Capvaxive |
| Optinose US, INC. | $153.96 | 2020-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.